<p>Aadi Bioscience, Inc.（纳斯达克：AADI - 获取免费报告）首席执行官 David James Lennon 于 3 月 3 日星期一出售了 5,690 股公司股票。该股票以平均价格 2.35 美元出售，总价值为 13,371.50 美元。出售后，首席执行官现在拥有 33,429 股公司股票，估值约为 78,558.15 美元。此次交易代表其持股减少了 14.55%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。</p>
<p>获取 <strong>Aadi Bioscience</strong> 警报：</p>
<h2>Aadi Bioscience 股票表现</h2>
<p>周一交易时段，AADI 股价下跌 0.26 美元，报 2.30 美元。公司交易了 217,778 股，较其平均交易量 174,224 股有所增加。该公司的市值为 5680 万美元，市盈率为-1.01，贝塔值为 0.64。该公司的 50 日移动平均线为 2.95 美元，200 日移动平均线为 2.37 美元。Aadi Bioscience, Inc.的 52 周最低价为 1.21 美元，52 周最高价为 3.81 美元。</p>
<h2>对 Aadi Bioscience 的对冲基金看法</h2>
<p>几家大型投资者最近对该公司的持股进行了调整。XTX Topco Ltd 在第三季度新购入了 Aadi Bioscience 的股份，价值约 32,000 美元。Two Sigma Advisers LP 在第四季度将其在 Aadi Bioscience 的持股增加了 95.2%。Two Sigma Advisers LP 现在拥有 61,686 股公司股票，价值 195,000 美元，此前在上个季度又购买了 30,086 股。Two Sigma Investments LP 在第四季度将其在 Aadi Bioscience 的持股增加了 305.2%。Two Sigma Investments LP 现在拥有 68,555 股公司股票，价值 216,000 美元，此前在上个季度又购买了 51,638 股。Northern Trust Corp 在第四季度将其在 Aadi Bioscience 的持股增加了 33.1%。Northern Trust Corp 现在拥有 91,151 股公司股票，价值 288,000 美元，此前在上个季度又购买了 22,677 股。最后，Bridgeway Capital Management LLC 在第四季度将其在 Aadi Bioscience 的持股增加了 23.7%。Bridgeway Capital Management LLC 现在拥有 115,400 股公司股票，价值 364,000 美元，此前在上个季度又购买了 22,100 股。机构投资者和对冲基金持有公司 52.08% 的股份。</p>
<h2>Aadi Bioscience 公司简介</h2>
<p>（获取免费报告）</p>
<p>Aadi Bioscience, Inc.是一家生物制药公司，专注于开发和商业化针对具有 mTOR 通路基因改变的基因定义癌症的精准疗法。其主要药物候选产品为 FYARRO，一种用于治疗晚期不可切除或转移性恶性 PEComa 的注射用西罗莫司蛋白结合颗粒。</p>
<h2>特色文章</h2>
<ul>
<li>五只我们更看好的股票，胜过 Aadi Bioscience</li>
<li>3 只小型股具有巨大的回报潜力</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求避难所</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>3 只超卖的七只奇迹股票处于关键水平：现在买入吗？</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>3M 预计在年中达到 175 美元，且更高的高点可能性较大</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ"/></p>
<p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Aadi Bioscience 吗？</h2>
<p>在考虑 Aadi Bioscience 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Aadi Bioscience 并不在名单上。</p>
<p>虽然 Aadi Bioscience 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

AADI

WHWK

<p>Aadi Bioscience, Inc. 首席执行官 David James Lennon 出售了 5,690 股股票，平均价格为 2.35 美元，总计 13,371.50 美元。出售后，他持有 33,429 股，价值约 78,558.15 美元，反映出其持股比例下降了 14.55%。该交易已向美国证券交易委员会（SEC）备案。Aadi 的股票交易价格下跌至 2.30 美元，市值为 5680 万美元。机构投资者持有该公司 52.08% 的股份，该公司专注于针对基因定义癌症的精准治疗</p>

<p>Aadi Bioscience, Inc. (NASDAQ:AADI - Get Free Report) CEO David James Lennon sold 5,690 shares of the company's stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $2.35, for a total value of $13,371.50. Following the sale, the chief executive officer now owns 33,429 shares of the company's stock, valued at approximately $78,558.15. This trade represents a 14.55 % decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.</p>
<div class="lb-trans"><p>Aadi Bioscience, Inc.（纳斯达克：AADI - 获取免费报告）首席执行官 David James Lennon 于 3 月 3 日星期一出售了 5,690 股公司股票。该股票以平均价格 2.35 美元出售，总价值为 13,371.50 美元。出售后，首席执行官现在拥有 33,429 股公司股票，估值约为 78,558.15 美元。此次交易代表其持股减少了 14.55%。该交易已在向 SEC 提交的文件中披露，您可以通过此链接访问。</p>
</div><p>Get <strong>Aadi Bioscience</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Aadi Bioscience</strong> 警报：</p>
</div><h2>Aadi Bioscience Stock Performance</h2>
<div class="lb-trans"><h2>Aadi Bioscience 股票表现</h2>
</div><p>Shares of AADI traded down $0.26 during trading hours on Monday, hitting $2.30. 217,778 shares of the company were exchanged, compared to its average volume of 174,224. The company has a market cap of $56.80 million, a PE ratio of -1.01 and a beta of 0.64. The firm's 50 day moving average is $2.95 and its 200-day moving average is $2.37. Aadi Bioscience, Inc. has a 52 week low of $1.21 and a 52 week high of $3.81.</p>
<div class="lb-trans"><p>周一交易时段，AADI 股价下跌 0.26 美元，报 2.30 美元。公司交易了 217,778 股，较其平均交易量 174,224 股有所增加。该公司的市值为 5680 万美元，市盈率为-1.01，贝塔值为 0.64。该公司的 50 日移动平均线为 2.95 美元，200 日移动平均线为 2.37 美元。Aadi Bioscience, Inc.的 52 周最低价为 1.21 美元，52 周最高价为 3.81 美元。</p>
</div><h2>Hedge Funds Weigh In On Aadi Bioscience</h2>
<div class="lb-trans"><h2>对 Aadi Bioscience 的对冲基金看法</h2>
</div><p>Several large investors have recently made changes to their positions in the business. XTX Topco Ltd acquired a new position in shares of Aadi Bioscience during the 3rd quarter worth about $32,000. Two Sigma Advisers LP lifted its position in shares of Aadi Bioscience by 95.2% during the 4th quarter. Two Sigma Advisers LP now owns 61,686 shares of the company's stock worth $195,000 after purchasing an additional 30,086 shares during the last quarter. Two Sigma Investments LP lifted its position in shares of Aadi Bioscience by 305.2% during the 4th quarter. Two Sigma Investments LP now owns 68,555 shares of the company's stock worth $216,000 after purchasing an additional 51,638 shares during the last quarter. Northern Trust Corp lifted its position in shares of Aadi Bioscience by 33.1% during the 4th quarter. Northern Trust Corp now owns 91,151 shares of the company's stock worth $288,000 after purchasing an additional 22,677 shares during the last quarter. Finally, Bridgeway Capital Management LLC lifted its position in shares of Aadi Bioscience by 23.7% during the 4th quarter. Bridgeway Capital Management LLC now owns 115,400 shares of the company's stock worth $364,000 after purchasing an additional 22,100 shares during the last quarter. Institutional investors and hedge funds own 52.08% of the company's stock.</p>
<div class="lb-trans"><p>几家大型投资者最近对该公司的持股进行了调整。XTX Topco Ltd 在第三季度新购入了 Aadi Bioscience 的股份，价值约 32,000 美元。Two Sigma Advisers LP 在第四季度将其在 Aadi Bioscience 的持股增加了 95.2%。Two Sigma Advisers LP 现在拥有 61,686 股公司股票，价值 195,000 美元，此前在上个季度又购买了 30,086 股。Two Sigma Investments LP 在第四季度将其在 Aadi Bioscience 的持股增加了 305.2%。Two Sigma Investments LP 现在拥有 68,555 股公司股票，价值 216,000 美元，此前在上个季度又购买了 51,638 股。Northern Trust Corp 在第四季度将其在 Aadi Bioscience 的持股增加了 33.1%。Northern Trust Corp 现在拥有 91,151 股公司股票，价值 288,000 美元，此前在上个季度又购买了 22,677 股。最后，Bridgeway Capital Management LLC 在第四季度将其在 Aadi Bioscience 的持股增加了 23.7%。Bridgeway Capital Management LLC 现在拥有 115,400 股公司股票，价值 364,000 美元，此前在上个季度又购买了 22,100 股。机构投资者和对冲基金持有公司 52.08% 的股份。</p>
</div><h2>Aadi Bioscience Company Profile</h2>
<div class="lb-trans"><h2>Aadi Bioscience 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.</p>
<div class="lb-trans"><p>Aadi Bioscience, Inc.是一家生物制药公司，专注于开发和商业化针对具有 mTOR 通路基因改变的基因定义癌症的精准疗法。其主要药物候选产品为 FYARRO，一种用于治疗晚期不可切除或转移性恶性 PEComa 的注射用西罗莫司蛋白结合颗粒。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Aadi Bioscience</li>
<li>3 Small Caps With Big Return Potential</li>
<li>Bearish Investors Can Seek Refuge in Recession-Resistant ETFs</li>
<li>What is a Stock Market Index and How Do You Use Them?</li>
<li>3 Oversold Magnificent Seven Stocks at Key Levels: Buy Now?</li>
<li>3 Natural Gas Stocks That Offer Great Dividend Yields</li>
<li>3M to Hit $175 by Mid-Year, and Higher Highs Are Likely</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Aadi Bioscience</li>
<li>3 只小型股具有巨大的回报潜力</li>
<li>看跌投资者可以在抗衰退 ETF 中寻求避难所</li>
<li>什么是股票市场指数，如何使用它们？</li>
<li>3 只超卖的七只奇迹股票处于关键水平：现在买入吗？</li>
<li>3 只天然气股票提供优厚的股息收益</li>
<li>3M 预计在年中达到 175 美元，且更高的高点可能性较大</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9QUFESQ" alt="" original-src="https://www.marketbeat.com/scripts/InsiderTradesChart.ashx?Prefix=NASDAQ&amp;Symbol=AADI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻警报由叙述科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快和最准确的报道。此故事在发布前已由 MarketBeat 的编辑团队审核。如对该故事有任何问题或意见，请发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Aadi Bioscience Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Aadi Bioscience 吗？</h2>
</div><p>Before you consider Aadi Bioscience, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Aadi Bioscience 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Aadi Bioscience wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄向客户推荐的股票，建议在更广泛的市场注意到之前买入……而 Aadi Bioscience 并不在名单上。</p>
</div><p>While Aadi Bioscience currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Aadi Bioscience 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

内幕交易：Aadi Biosciences, Inc.（纳斯达克股票代码：AADI）首席执行官出售 5690 股股票